Introduction {#Sec1}
============

It is widely accepted that beta cell function progressively deteriorates in individuals with type 2 diabetes mellitus as described, for example, by the UK Prospective Diabetes Study \[[@CR1]\]. To prevent diabetic complications, maintenance of strict glycaemic control is necessary, but this requires preservation of beta cell function. On the other hand, human diabetic patients exhibit an early defect in glucose-stimulated insulin secretion (GSIS) \[[@CR2]\] and autopsy studies have demonstrated reduced beta cell mass in diabetic patients \[[@CR3]\]. Thus, development of treatment strategies has focused on ways to improve beta cell function and to prevent beta cell death. Hence, there is increased interest in determining whether newer drugs such as insulin-sensitising agents produce sustained improvements in beta cell function \[[@CR4], [@CR5]\]. Likewise, agents associated with glucagon-like peptide-1 (GLP-1) have also attracted considerable attention because they may alter the natural history of type 2 diabetes by preserving pancreatic beta cell mass \[[@CR6]--[@CR8]\] and function \[[@CR9]--[@CR11]\].

GLP-1 has several beneficial effects that counteract the pathophysiology of diabetes mellitus. First, GLP-1 is a potent glucose-lowering polypeptide that induces glucose-dependent insulin secretion \[[@CR12], [@CR13]\] while suppressing glucagon secretion \[[@CR14], [@CR15]\]. Second, GLP-1 has extra-pancreatic effects, such as delayed gastric emptying \[[@CR16], [@CR17]\], appetite suppression \[[@CR18]\] and improved insulin sensitivity \[[@CR19]\]. Third and last, GLP-1 stimulates beta cell replication \[[@CR20], [@CR21]\], neogenesis \[[@CR22]\] and differentiation \[[@CR22]\], as well as inhibiting beta cell apoptosis via reduction of cellular stress \[[@CR23]--[@CR26]\]. Consequently, GLP-1-related agents are currently regarded as a powerful treatment option for type 2 diabetes \[[@CR27], [@CR28]\]. Liraglutide, a novel long-acting GLP-1 derivative, is resistant to dipeptidyl peptidase-IV. Its prolonged effects result from the substitution of Lys for Arg34 and the addition of a glutamic acid and a 16C NEFA to the Lys26 residue of native GLP-1 \[[@CR29]\].

To investigate the molecular mechanism by which liraglutide preserves pancreatic beta cell mass, we treated obese diabetic *db/db* mice with liraglutide for 2 days or 2 weeks. We also treated normoglycaemic *m/m* mice with liraglutide for 2 weeks.

Methods {#Sec2}
=======

**Animals** Male 9-week-old BKS.Cg-+ *Lepr*^*db*^/+ *Lepr*^*db*^/Jcl (*db/db*) mice and BKS. Cg-*m*+/*m*+/Jcl (*m/m*) mice were purchased (Clea, Tokyo, Japan). They were housed two to three animals per cage in all experiments under controlled ambient conditions and a 14:10 h light/dark cycle with lights on at 07:00 hours. Animals were given free access to drinking water and conventional food (Oriental Yeast, Tokyo, Japan). They received a subcutaneous injection of liraglutide (200 μg/kg) or vehicle (PBS) twice daily (09:00 and 16:00 hours). Doses of the peptides used in the study were based on a review of the literature \[[@CR7]\]. Body weight and food intake were monitored weekly from 9 weeks of age. All experiments were approved by the Kawasaki Medical School Animal Experiment Committee (No. 06-062) and were performed in accordance with the Kawasaki Medical School guidelines for animal experiments.

**Measurement of biochemical markers** Blood samples were collected from the tail vein once per week. Blood glucose was measured immediately using a commercially available enzyme electrode method (FreeStyle; Kissei Pharmaceutical, Nagano, Japan). Plasma was separated and stored at −80°C until use. The concentration of insulin in the plasma was measured using an ELISA kit (Morinaga Institute of Biological Science, Yokohama, Japan) and the plasma triacylglycerol concentration was determined enzymatically (E-Test; Wako, Osaka, Japan).

**Insulin tolerance test** After the 2 day or 2 week liraglutide treatment in *db/db* mice, an insulin tolerance test was performed by a intraperitoneal injection of insulin (2 units/kg body weight) after an overnight fast. Blood samples were collected from the tail vein every 30 min and blood glucose was determined immediately as described above.

**Measurement of insulin content in pancreatic islets** Pancreatic islets were isolated using the collagenase digestion method as previously described \[[@CR30]\]. Briefly, Hanks' balanced salt solution containing 1.5 mg/ml collagenase (Collagenase P; Roche, Basel, Switzerland) and 10% (vol./vol.) fetal calf serum was infused into the bile duct. The excised pancreas was transferred to Hanks' balanced salt solution and centrifuged three times for 2 min each time at 1,100 rpm (200 *g*). The final pellet was passed through a metal filter and the filtrate was centrifuged for 22 min at 2,500 rpm (1,000 *g*) using Histopaque-1077 (Sigma, St Louis, MO, USA). The islet samples were stored at −80°C until measurement of insulin content.

**Measurement of triacylglycerol content in pancreatic islets** Pancreatic islets were isolated as described above and 45--60 of the isolated pancreatic islets were washed twice in PBS, to which 50 μl of a high-salt buffer (2 mol/l NaCl, 2 mmol/l EDTA, 50 mmol/l sodium phosphate) was added, followed by sonication for 1 min to disrupt the pancreatic islets. After centrifugation for 5 min at 12,000 rpm (13,000 *g*), 10 μl of the supernatant fraction was mixed with 10 μl *t*-butanol plus 50 μl Triton X-100-methyl alcohol (1:1). Triacylglycerol content in the pancreatic islets was measured using E-Test (Wako) according to the manufacturer's instructions.

**Glucose-stimulated insulin secretion from isolated pancreatic islets** Size-matched pancreatic islets were prepared (five pancreatic islets per tube) and preincubated in KRB-HEPES buffer containing 5 mg/ml BSA, pH 7.4, and 95% O~2~/5% CO~2~ saturated at 37°C for 60 min. The supernatant fraction was replaced with a 3.0 or 16.7 mmol/l glucose solution, and the mixture was incubated for an additional 60 min. The supernatant fraction was recovered and stored at −80°C until the insulin assay was performed.

**Immunohistochemistry** Pancreas tissue sections (4 μm) were stained with haematoxylin--eosin. For immunostaining, the sections were immersed for 15 min in methanol containing 3% (vol./vol.) hydrogen peroxide to block endogenous peroxidase activity. After rinsing with PBS (10 mmol/l, pH 7.0), the sections were incubated for 1 h with a mixture of antibodies (rabbit anti-glucagon antibody: anti-somatostatin antibody 1:1; Nichirei, Tokyo, Japan) at 25°C. Tissue sections were also incubated for 14 h at 4°C with either a mouse anti-insulin monoclonal antibody, an anti-proliferative cell nuclear antigen (PCNA) monoclonal antibody (Nichirei) or a mouse anti-4-hydroxy-2-noneal modified protein (4HNE) monoclonal antibody (25 μg/ml; Japan Institute for the Control of Aging, Shizuoka, Japan). After rinsing with PBS, simple stain diaminobenzidine solution (Nichirei) was added and the mixture was incubated for 7 min at 25°C. The sections were counterstained with haematoxylin. To investigate cell apoptosis, a TUNEL assay was performed using a colorimetric apoptotic detection system (DeadEnd; Promega, Madison, WI, USA), as described previously \[[@CR31]\].

**Morphometric analysis** The image analysis software NIH Image (Version 1.61; <http://rsbweb.nih.gov/ij/>) was used to calculate the entire pancreatic area, islet area and glucagon- and somatostatin-positive cells, and also to determine the relative islet area and the relative beta cell area. Using 15 sections (i.e. five sections from three different areas of the pancreas) for each group of mice, beta cell mass was estimated by the following formula: beta cell mass (mg) = the pancreas weight (mg) × per cent pancreatic islet area × percent beta cell count.

**Laser capture microdissection** According to our previously established procedure \[[@CR32]\], frozen, 8 μm thick tissue slices were immediately stained and subjected to laser capture microdissection. After tissue staining, the islets were irradiated with a laser using the PixCell system (Arcturus, Mountain View, CA, USA). The peripheral area was first removed and then the beta-cell-rich core area was collected.

**Real-time PCR** RNA was extracted using an RNA isolation kit (PicoPure PN 12206-01; Arcturus). TaqMan reverse transcription reagents (N808-0234; Applied Biosystems, Foster, CA, USA) were used for reverse transcription and random hexamers were used as primers for cDNA synthesis. The primers were designed using Primer Express (Applied Biosystems) and were based on mRNA sequences downloaded from the GenBank nucleotide database ([www.ncbi.nlm.nih.gov/nuccore](http://www.ncbi.nlm.nih.gov/nuccore)).A reaction solution was prepared by combining 0.5 μl of the sample, 1 μl of a 50 nmol/l primer solution, 5 μl Sybr Green PCR Master Mix (Applied Biosystems) solution and 3.5 μl diluent. Dissociation curve analysis was performed for each experiment to determine the dissociation temperature and the size of the PCR products was confirmed by agarose gel electrophoresis. We examined gene expression in the core area of the pancreatic islets, selecting primary genes for which a statistically significant difference between the groups in the first gene expression experiment had been observed. The genes analysed in the present study were those associated with cell differentiation (*Hlxb-9* \[also known as *Mnx1*\], *Hes1*, *Neurod* \[also known as *Neurod1*\] and *Pdx1*), cell proliferation (*CycD* and *Erk-1* \[also known as *Mapk3*\]), endoplasmic reticulum (ER) stress (*Xbp1*), antioxidative stress (*Cat* and *Gpx*), lipid synthesis (*Srebp-1c* \[also known as *Srebf1*\] and *Fas*) and cell apoptosis (*Bcl2, Casp8*, *Casp3* and *Cad*). To quantify gene expression, $\documentclass[12pt]{minimal}
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**Statistical analysis** All data are presented as means ± SEM. A Mann--Whitney *U* test was used to test for differences among multiple groups, with *p* \< 0.05 regarded as significant. The statistical analyses were performed with StatView (version 5; SAS, Cary, NC, USA).

Results {#Sec3}
=======

**Metabolic variables in *db/db* mice with chronic liraglutide treatment** After 1 week of treatment, liraglutide significantly decreased food intake (23.7 ± 1.6 vs 39.8 ± 0.8 g per week, *p* \< 0.0001; Fig. [1a](#Fig1){ref-type="fig"}) and suppressed body weight gain (41.3 ± 0.4 vs 43.3 ± 0.5 g, *p* \< 0.05; Fig. [1b](#Fig1){ref-type="fig"}) in *db/db* mice compared with vehicle-treated mice. Liraglutide also reduced fasting glucose (7.0 ± 0.4 vs 9.4 ± 0.6 mmol/l, *p* \< 0.05; Fig. [1c](#Fig1){ref-type="fig"}) and insulin concentrations (567.9 ± 51.6 vs 1,032 ± 86.1 pmol/l, *p* \< 0.01; Fig. [1d](#Fig1){ref-type="fig"}) in *db/db* mice after 1 week of treatment. These effects were sustained by prolonged intervention with liraglutide until 2 weeks, at which time the liraglutide-treated group had a significant improvement in hypertriacylglycerolaemia (1.3 ± 0.03 vs 1.5 ± 0.07 mmol/l, *p* \< 0.01; Fig. [1e](#Fig1){ref-type="fig"}). We also found that brief liraglutide treatment, i.e. for 2 days, resulted in similar metabolic improvements (Fig. [2a, b, d](#Fig2){ref-type="fig"}). The exception was fasting insulin, which was increased by 2 days of liraglutide treatment compared with vehicle (826.1 ± 86.1 vs 567.9 ± 34.4 pmol/l, *p* \< 0.05; Fig. [2c](#Fig2){ref-type="fig"}). Insulin sensitivity in *db/db* mice was improved only after 2 weeks of liraglutide treatment (Figs [1f](#Fig1){ref-type="fig"}, [2e](#Fig2){ref-type="fig"}). Fig. 1Metabolic variables in diabetic *db/db* mice treated for 2 weeks with vehicle (diamonds) or liraglutide (squares). **a** Food intake, (**b**) body weight, (**c**) Fasting blood glucose, (**d**) fasting plasma insulin concentration, (**e**) fasting plasma triacylglycerol concentration and (**f**) insulin sensitivity assessed by an i.p. insulin tolerance test. Results of the insulin tolerance test are expressed as a percentage relative to the basal blood glucose concentration before insulin administration. *n* = 7 for each group; \**p* \< 0.05, \*\**p* \< 0.01, \*\*\**p* \< 0.001; ^†^*p* \< 0.005Fig. 2Metabolic variables in diabetic *db/db* mice treated for 2 days with vehicle (black bar, diamonds) or liraglutide (white bar, black squares). **a** Body weight (BW) change, (**b**) fasting blood glucose, (**c**) fasting plasma insulin concentration, (**d**) fasting plasma triacylglycerol concentration and (**e**) insulin sensitivity assessed by i.p. insulin tolerance test. Results of the tolerance test are expressed as a percentage relative to the basal blood glucose concentration before insulin administration. *n* = 11 for each group; \**p* \< 0.05, \*\*\**p* \< 0.001

**Islet function and morphology in *db/db* mice treated with liraglutide** To investigate whether 2 weeks of liraglutide treatment exerted beneficial effects on the pancreatic islets of *db/db* mice, we first subjected isolated pancreatic islets to morphological analysis and immunostaining with antibodies against glucagon and somatostatin. While liraglutide treatment in *db/db* mice conserved the normal morphology of pancreatic islets, in which glucagon- and somatostatin-positive cells were observed in the periphery, vehicle treatment disrupted these structures (Fig. [3a](#Fig3){ref-type="fig"}). In addition, beta cell mass was significantly increased in liraglutide-treated *db/db* mice, compared with vehicle-treated mice (7.7 ± 0.7 vs 4.9 ± 0.5 mg, *p* \< 0.01; Fig. [3b](#Fig3){ref-type="fig"}). Fig. 3Islet morphology and function in *db/db* mice treated with vehicle (black bars) or liraglutide (white bars) for 2 days or 2 weeks. **a** Haematoxylin--eosin staining, followed by double immunohistochemical staining with antibodies against glucagon and somatostatin. Scale bars 100 μm. **b** Beta cell mass, measured as described; *n* = 5 (**a, b**). **c** Immunohistochemical staining with antibodies against PCNA, quantified (**d**) as ratio. **e, f** 4-HNE and (**g, h**) TUNEL assays and quantification as indicated. **c--h***n* = 3 for each assay, scale bars 100 μm. The proportion of cells positive for PCNA (**c, d**) and 4-HNE (**e, f**) was measured in each islet and expressed as average proportion for a minimum of 50 islets from each experimental animal. DNase-treated cells were used as a positive control in the TUNEL assay (**g, h**), with results of the TUNEL assay expressed as the average number of TUNEL-positive cells per islet by assessing a minimum of 50 islets from each experimental animal. **i** Islet insulin content and **(j**) islet triacylglycerol content; *n* = 5. **k** GSIS was assessed by use of lower and higher glucose concentrations (3 mmol/l and 16.7 mmol/l); *n* = 5. \**p* \< 0.05, \*\**p* \< 0.01After the 2 week intervention, islet insulin content in liraglutide-treated *db/db* mice was greater than that in *db/db* mice treated with vehicle for 2 weeks (33.7 ± 2.3 vs 17.2 ± 2.1 ng/islet, *p* \< 0.01; Fig. [3i](#Fig3){ref-type="fig"}). Although islet insulin content in vehicle-treated *db/db* mice tended to decrease with age (2 days 24.7 ± 2.7 vs 2 weeks 17.2 ± 2.1 ng/islet, *p* = 0.1; Fig. [3i](#Fig3){ref-type="fig"}), that in mice treated with liraglutide for 2 weeks was increased compared with mice treated with liraglutide for 2 days (2 weeks 33.7 ± 2.3 vs 2 days 27.0 ± 1.7 ng/islet, *p* \< 0.05; Fig. [3i](#Fig3){ref-type="fig"}).After 2 weeks of liraglutide treatment, insulin secretion was increased in response to 16.7 mmol/l glucose, but not to 3 mmol/l (1.5 ± 0.2 vs 0.9 ± 0.1 ng/ml per islet, *p* \< 0.05; Fig. [3k](#Fig3){ref-type="fig"}). However, 2 days of liraglutide treatment had no effect on insulin secretion, irrespective of glucose concentration (Fig. [3k](#Fig3){ref-type="fig"}). These results suggest that chronic liraglutide treatment improved the reactivity of pancreatic beta cells in response to the higher glucose concentration.Next, we examined the effect of liraglutide treatment on islet triacylglycerol content, which was not affected by 2 days of liraglutide treatment (Fig. [3j](#Fig3){ref-type="fig"}), although hypertriacylglycerolaemia was improved (Fig. [2d](#Fig2){ref-type="fig"}). However, the accumulation of triacylglycerol in the pancreatic islets was prevented by 2 weeks of liraglutide treatment (Fig. [3j](#Fig3){ref-type="fig"}), despite an increase in islet triacylglycerol content with ageing in vehicle-treated mice.A morphological examination was used to study the mechanisms involved in the restoration of pancreatic beta cell mass by liraglutide in *db/db* mice. Histological sections of the pancreatic islet were stained by an antibody specific for PCNA and the proportion of antibody-positive cells was measured to evaluate the proliferative effect on pancreatic islets. Liraglutide-treated mice exhibited a significant increase in PCNA-positive cells in pancreatic islets (Fig. [3c, d](#Fig3){ref-type="fig"}). Oxidative stress, which was evaluated by scoring 4-HNE-positive cells in pancreatic islets, was reduced in the pancreatic islets of liraglutide-treated mice (Fig. [3e, f](#Fig3){ref-type="fig"}), while cellular apoptosis, analysed by a TUNEL assay, was suppressed (Fig. [3g, h](#Fig3){ref-type="fig"}).

**Effect of liraglutide on gene expression in pancreatic beta cells of *db/db* mice** Both 2 weeks and 2 days of liraglutide treatment significantly augmented expression of genes involved in cellular differentiation (*Hlxb-9*, *Neurod* and *Pdx1*; Fig. [4a, c, d, g, i, j](#Fig4){ref-type="fig"}) and significantly reduced expression of an anti-differentiation gene (*Hes1*) in pancreatic beta cells of *db/db* mice (Fig. [4b, h](#Fig4){ref-type="fig"}). The expression of genes involved in cellular proliferation (*CycD* and *Erk-1*) was also increased significantly in *db/db* mice treated with liraglutide for 2 weeks, with similar results obtained in mice treated for 2 days (Fig. [4e, f, k, l](#Fig4){ref-type="fig"}). Liraglutide also significantly increased expression of the anti-apoptotic *Bcl2* gene (Fig. [4m, q](#Fig4){ref-type="fig"}) and reduced expression of pro-apoptotic genes (*Casp8*, *Casp3* and *Cad*) in both treatment regimens (Fig. [4n, o, p, r, s, t](#Fig4){ref-type="fig"}). Fig. 4Gene expression in the core area of islets in *db/db* mice treated with vehicle (black bars) or liraglutide (white bars). **a--f** Expression of genes involved in cell differentiation and proliferation after 2 weeks and (**g--l**) 2 days of treatment. **a, g***Hlxb-9*, (**b, h**) *Hes1*, (**c, i**) *Neurod*, (**d, j**) *Pdx1*, (**e, k**) *Erk1*, (**f, l**) *CycD*. **m--t** Expression of genes involved in pro-apoptosis and anti-apoptosis after 2 weeks (**m--p**) and 2 days (**q--t**) of treatment. **m, q***Bcl2*, (**n, r**) *Casp8*, (**o, s**) *Casp3*, (**p, t**) *Cad*. **u--dd** Expression of genes involved in anti-oxidative stress, ER stress and lipid synthesis after 2 weeks (**u--y**) and 2 days (**z--dd**) of treatment. **u, z***Gpx*, (**v, aa**) *Cat*, (**w, bb**) *Xbp1*, (**x, cc)***Fas*, (**y, dd)***Srebp-1c*. *n* = 4 for each group; \**p* \< 0.05, \*\**p* \< 0.01; ^†^*p* \< 0.005; ^‡^*p* \< 0.0001; ^§^*p* = 0.08In contrast, chronic but not acute liraglutide treatment significantly increased the expression of genes involved in anti-oxidative stress (*Cat* and *Gpx*; Fig. [4u, v, z, aa](#Fig4){ref-type="fig"}) and significantly reduced those related to ER stress (*Xbp1*; Fig. [4w, bb](#Fig4){ref-type="fig"}) and lipid synthesis (*Srebp-1c* and *Fas*) in beta cells of *db/db* mice (Fig. [4x, y, cc, dd](#Fig4){ref-type="fig"}). The expression profile of *Srebp-1c* and *Fas* (Fig. [4x, y, cc, dd](#Fig4){ref-type="fig"}), which was consistent with islet triacylglycerol content (Fig. [3j](#Fig3){ref-type="fig"}), indicated that liraglutide alleviates the lipotoxicity experienced by beta cells in a time-dependent fashion. Together, these results suggest that liraglutide directly accelerates cellular differentiation and proliferation, and inhibits apoptosis via a reduction in oxidative and ER stress mediated by improvements in glucolipotoxicity.

**Impact of liraglutide on metabolism in normoglycaemic mice** We next investigated the effect of liraglutide in normoglycaemic *m/m* mice, which were treated with or without liraglutide for 1 week. Food intake in *m/m* mice, compared with the vehicle-treated group, was significantly reduced by liraglutide treatment (21.1 ± 0.8 vs 27.9 ± 1.0 g/week, *p* \< 0.05; Fig. [5a](#Fig5){ref-type="fig"}), as was body weight gain (20.1 ± 0.2 vs 22.2 ± 0.9 g, *p* \< 0.05; Fig. [5b](#Fig5){ref-type="fig"}). These effects were sustained by prolonged liraglutide treatment for up to 2 weeks, but were not correlated with metabolic variables, such as fasting concentrations of blood glucose, insulin and triacylglycerol, which did not differ statistically between liraglutide-treated and vehicle-treated *m/m* mice (Fig. [5c--e](#Fig5){ref-type="fig"}). Fig. 5Metabolic variables in normoglycaemic *m/m* mice treated with vehicle (diamonds) or liraglutide (squares). **a** Food intake, (**b**) body weight, (**c**) fasting blood glucose, (**d**) fasting plasma insulin concentration and (**e**) fasting plasma triacylglycerol concentration. *n* = 5 for each group; \**p* \< 0.05, \*\**p* \< 0.01

**Effect of liraglutide on morphology, function and gene expression of pancreatic beta cells in normoglycaemic mice** In *m/m* mice, beta cell mass and islet insulin content were significantly increased by liraglutide treatment (1.0 ± 0.1 vs 0.7 ± 0.1 mg, *p* \< 0.01; 59.0 ± 3.7 vs 44.4 ± 3.9 ng/islet, *p \<* 0.05; Fig. [6a, b](#Fig6){ref-type="fig"}). The increases in beta cell mass and islet insulin content were associated with improvements in GSIS in isolated islets in response to 16.7 mmol/l glucose (1.6 ± 0.1 vs 1.2 ± 0.03 ng/ml per islet, *p* \< 0.05; Fig. [6c](#Fig6){ref-type="fig"}) in the liraglutide-treated group compared with the vehicle-treated group. Fig. 6Islet morphology and islet function in *m/m* mice treated for 2 weeks with vehicle (black bars) or liraglutide (white bars). **a** Pancreatic beta cell mass, (**b**) islet insulin content and (**c**) GSIS. **d** Immunohistochemical staining of the pancreatic islet with antibodies against PCNA, (**e**) 4-HNE and (**f**) TUNEL. *n* = 4 for each group; \**p* \< 0.05, \*\**p* \< 0.01The number of PCNA-positive cells was significantly increased (Fig. [6d](#Fig6){ref-type="fig"}), suggesting that the proliferation of pancreatic islets was upregulated in liraglutide-treated *m/m* mice. Nevertheless, the numbers of 4-HNE-positive and TUNEL-positive cells in the pancreatic islets did not differ between liraglutide- and vehicle-treated *m/m* mice (Fig. [6e, f](#Fig6){ref-type="fig"}). At the level of mRNA expression, *m/m* mice treated with liraglutide for 2 weeks experienced a significant increase in expression of genes involved in cellular differentiation (*Hlxb-9*, *Neurod* and *Pdx1*; Fig. [7a, c, d](#Fig7){ref-type="fig"}) and proliferation (*Erk-1* and *CycD*; Fig. [7e, f](#Fig7){ref-type="fig"}), along with a significant reduction in expression of an anti-differentiation gene (*Hes1*; Fig. [7b](#Fig7){ref-type="fig"}). The expression of mRNA for genes associated with cell apoptosis, anti-oxidative stress, ER stress and lipid synthesis was not statistically different between liraglutide- and vehicle-treated mice (Fig. [7g--o](#Fig7){ref-type="fig"}). These results suggest that liraglutide affects beta cell mass by stimulating cellular differentiation and proliferation without affecting blood glucose, insulin or triacylglycerol concentrations. Fig. 7Gene expression in the core area of islets in *m/m* mice treated with vehicle (black bars) or liraglutide (white bars) for 2 weeks. **a--f** Expression of genes involved in cell differentiation and proliferation, i.e. (**a**) *Hlxb-9*, (**b**) *Hes1*, (**c**) *Neurod*, (**d**) *Pdx1*, (**e**) *Erk1* and (**f**) *CycD*. **g--j** Expression of genes involved in cell apoptosis, i.e. (**g**) *Bcl2*, (**h**) *Casp8*, (**i**) *Casp3* and (**j**) *Cad*. **k--o** Expression of genes involved in anti-oxidative stress, ER stress and lipid synthesis, i.e. (**k**) *Gpx*, (**l**) *Cat*, (**m**) *Xbp1*, (**n)***Fas* and (**o)***Srebp-1c*. *n* = 4 for each group; \**p* \< 0.05; ^†^*p* \< 0.005

Discussion {#Sec4}
==========

In the present study, we investigated the effects of liraglutide on obese diabetic mice. We found that the beta cell mass of *db/db* mice was increased by long-term liraglutide treatment. These results are essentially consistent with previous reports describing a stimulatory effect on beta cell mass of exendin-4, a potent GLP-1 receptor agonist, in a partial pancreatectomy rat model of type 2 diabetes \[[@CR20]\] and of liraglutide, the long-acting GLP-1 derivative, in diabetic *db/db* mice \[[@CR7]\].

The present results demonstrate that short- and long-term treatment with liraglutide affected mRNA expression of *Hlxb-9*, *Hes1* and *Neurod* in the core of islets in diabetic *db/db* mice. The roles of several genes with well defined functions in pancreatic development, such as those mentioned above (*Hlxb9*, *Hes-1* and *Neurod*) have not been previously studied in the adult pancreas. On the other hand, previous studies have suggested that the Notch signal through hairy and enhancer of split-1 (HES1) is activated even in the adult pancreas in conditions associated with cell regeneration, such as inflammation and neoplasia in the pancreas \[[@CR33], [@CR34]\]. In addition, a recent in vitro study also demonstrated that HES1 is involved in determining the beta cell fate of adult human beta cells \[[@CR35]\]. These findings suggest the possibility that genes associated with an early stage of endocrine pancreas development are expressed in adult *db/db* mice and that liraglutide affects the expression of those genes. However, the present results cannot be regarded as conclusive, and further studies will be required to elucidate this issue.

In this study, cell proliferation related to *CycD* and *Erk-1* gene expression was readily upregulated in diabetic and normoglycaemic mice treated with liraglutide for 2 days. Immunohistochemical analysis of the pancreatic islets suggested that enhancement of cellular proliferation might be an underlying mechanism that accounts for the restorative effects of GLP-1 on pancreatic beta cell mass. These results strongly support the hypothesis that liraglutide affects pancreatic beta cell mass by directly stimulating cellular proliferation. Interestingly, a previous study demonstrated that pancreatic beta cell mass in non-diabetic rats was significantly increased after 1 week of liraglutide treatment, but no different from that in control animals after 6 weeks of treatment, indicative of a temporary effect on beta cell mass \[[@CR36]\]. This result suggests that the effect of liraglutide on beta cell kinetics is acute and temporary in non-diabetic conditions.

The binding of GLP-1 to its receptors activates adenylate cyclase and the cyclic AMP/protein kinase A signalling pathway. Additionally, GLP-1 activates phosphoinositide 3-kinase (PI3K), p42 mitogen-activated protein kinase (MAPK) and the epidermal growth factor receptor \[[@CR37]--[@CR39]\]. Furthermore, activation of the transcription factor for *Pdx1* \[[@CR38]\], p38 MAPK and protein kinase C-zeta \[[@CR40]\] reportedly plays a role in GLP-1-induced DNA synthesis and replication. Thus there is emergent evidence for extensive cross-talk between the G-protein-coupled receptor and tyrosine kinase-coupled receptor signalling pathways in beta cells. The results of the present study show that modulation of the *CycD* gene is involved in the liraglutide-induced increase in beta cell mass, presumably through the MAPK pathway. We also found that cellular differentiation is affected by liraglutide via upregulation of *Pdx1*, which is located downstream of the PI3K--protein kinase B--forkhead box O1 pathway.

Liraglutide modified the expression of genes related to cell apoptosis such as *Bcl2*, *Casp8*, *Casp3* and *Cad* in *db/db* mice during short- and long-term treatment, whereas mRNA levels of these genes were not altered in normoglycaemic *m/m* mice, suggesting that liraglutide directly suppressed beta cell apoptosis in mice under hyperglycaemic conditions. In a previous report, extracellular signal-regulated kinase (ERK)1/2 regulated *Bcl2* gene expression and protein production, as well as the activity of caspase 3 through the regulation of cyclic AMP-responsive element-binding protein \[[@CR41]\]. Furthermore, the extracellular matrix directly suppressed caspase 8 activity through regulation of the ERK but not the PI3K pathway in pancreatic beta cells \[[@CR42]\]. These results indicate that liraglutide may have a direct anti-apoptotic effect, which is at least partly mediated by ERK.

With regard to the effect of GLP-1 on oxidative stress, Tews and co-workers \[[@CR26]\] reported that exendin-4 directly reduces oxidative stress through counterregulation of the reduced abundance of electron transport chain proteins in INS-1 beta cells. In the present study, immunohistological analysis with anti-4-HNE staining and the TUNEL assay showed that 2 weeks of liraglutide treatment inhibited cellular oxidative stress and apoptosis of the pancreatic islets in diabetic *db/db* mice. We also showed that 2 weeks, but not 2 days of liraglutide treatment suppressed expression of *Cat* and *Gpx*. The expression of *Srebp-1c* and *Fas* mRNAs, as well as islet triacylglycerol content were also decreased only by the 2 week liraglutide treatment regimen. These results suggest that, in contrast to the action of exendin-4 in cultured cell lines, the improvements in oxidative stress observed with liraglutide treatment in *db/db* mice are secondary to improvements in glucolipotoxicity.

The inhibitory effect of long-term liraglutide treatment on expression of *Xbp1* in the core area of pancreatic islets, which should reflect a decrease in the unfolded protein accumulated in the ER of pancreatic beta cells, is essentially consistent with the findings of Yusta et al., who reported that chronic administration of exendin-4 decreased expression of *Chop* (also known as *Ddit3*) and spliced *Xbp1* in the pancreatic islets of *db/db* mice \[[@CR43]\]. They also found that exendin-4 potentiated the induction of activating transcription factor 4, a transcription factor mediated by phosphorylated eukaryotic translation initiation factor 2 α (eIF2α), in the INS-1 beta cell in a manner that is dependent on protein kinase A, accelerating recovery from ER stress-mediated translational repression by growth arrest and DNA-damage-inducible 34, which promotes eIF2α dephosphorylation \[[@CR43]\]. Contrary to the in vitro findings reported by Yusta et al. \[[@CR43]\], the present in vivo study demonstrated that even short-term liraglutide treatment did not affect expression of *Xbp1* in hyperglycaemic mice. The different study conditions, in vivo and in vitro experiments, may have led to these different results.

Fehmann and Habener demonstrated a stimulatory effect of GLP-1 on proinsulin biosynthesis in insulinoma beta TC-1 cells \[[@CR9]\]. In the present study, we found that liraglutide enhanced the responsiveness of beta cells to a glucose challenge in diabetic and normoglycaemic mice. These results are essentially consistent with previous studies that have reported an improved responsiveness of the pancreatic beta cells to glucose when isolated mouse islets were incubated with liraglutide \[[@CR10]\].

In conclusion, we have demonstrated that liraglutide restores pancreatic beta cell mass due to acute effects on cell kinetics and chronic effects on oxidative and ER stress that are secondary to improvements in glucolipotoxicity. These conclusions were mainly obtained by analysing the changes of gene expression in pancreatic islet cells. To fully understand the effect of liraglutide on pancreatic beta cell mass, further investigations, e.g. assessing the effect of liraglutide on peptide expression and function, as well as its role in neogenesis from the ducts, should be conducted.
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